You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The GD2-directed treatment had varying degrees of activity in a small Phase I study, though further improvements are needed to achieve durable responses.
The Phase I/II trial of PC14586 will involve patients with advanced solid tumors characterized by the p53 Y220C mutation.
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.
The trial is evaluating BP1002 to treat lymphoma and chronic lymphocytic leukemia patients whose tumors overexpress the protein BCL-2.
The Phase I trial will assess BBP-398's safety and anti-tumor activity in cancers with MAPK signaling pathway genetic mutations, including mutations in RAS genes.
In the wake of encouraging interim results, Moderna plans to expand the head and neck cancer cohort of its mRNA-4157 plus Keytruda clinical trial.
The company's T-cell product, PRIME IL-15, which is loaded with an IL-15fc nanogel, led 10 out of 17 advanced solid tumor patients to have stable disease.
The agency ordered Poseida to halt the trial in August after a patient died but is now allowing the company to resume the study with an amended protocol.
The Phase I/II trials will study Reqorsa in combination with Merck's Keytruda and AstraZeneca's Tagrisso in certain molecularly defined lung cancer subgroups.
A Phase I study used a less toxic dosing schedule that yielded encouraging response rates in patients with difficult-to-treat KRAS-mutated cancers.